^
Association details:
| Biomarker: | EGFR G465R |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer
Excerpt:
Acquired resistance to cetuximab was associated with the emergence of mutations, which occurred mainly in KRAS, NRAS, and EGFR genes (Table 2). An EGFR G465R mutation (22% of mutant alleles) was detected in a biopsy from a patient which had been previously treated with cetuximab.
DOI:
10.1158/1078-0432.CCR-15-2400
